Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Hackensack › NPI 1568839173
Lab

Ridgewood Diagnostic Laboratory, LLC

Ridgewood Diagnostic Laboratory, LLC was paid $14.72M by Medicaid between Mar 2018 and Mar 2023, across 28 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 68% of everything it billed.

33Billing provider infoRIDGEWOOD DIAGNOSTIC LABORATORY, LLC
HACKENSACK, NJ 07601
33aNPI1568839173assigned 08/31/2015
28Total paid$14.72M
24GClaims416,825
24DCodes billed28
24AFirst – last monthMar 2018 – Mar 2023
Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#21 of 122
Median peer was paid$1.29M
This provider vs. median11×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,540$31K
201986$6K
202015,697$531K
2021236,111$8.45M
2022163,374$5.70M
202317$0.00
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 68% 145,405 88,831 $10.00M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 21% 136,248 83,606 $3.02M
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 11% 130,913 77,507 $1.61M
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 650 591 $26K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 593 379 $18K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 282 202 $11K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 812 464 $10K
86003 <1% 55 55 $7K
87150 <1% 300 219 $7K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 128 115 $4K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 155 77 $3K
86769 <1% 97 48 $2K
16 more codes
87581 <1% 301 $846.34
87486 <1% 274 $846.34
87541 <1% 282 $790.71
82785 <1% 55 $627.90
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 22 $51.33
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 0% 23 $0.00
87532 0% 23 $0.00
87640 0% 23 $0.00
87496 0% 23 $0.00
87503 0% 23 $0.00
87498 0% 23 $0.00
87799 0% 23 $0.00
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 0% 23 $0.00
87653 0% 23 $0.00
87634 0% 23 $0.00
87631 0% 23 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZAITSEV, ALEXANDR (PRESIDENT)
Same official

Other billing entities under ZAITSEV, ALEXANDR

Full network →
ProviderLocationPaid
Universal Diagnostic Laboratory LLCHollywood, FL$1.10M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.